Gabapentin enacarbil extended release for the treatment of postherpetic neuralgia in adults

Therapeutics and Clinical Risk Management

Volumn 9, Issue 1, 2013, Pages 469-475

  Thomas, Ben M ^a   Farquhar Smith, Paul ^b  

^a CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

Garbapentin enacarbil; Herpes zoster; Postherpetic neuralgia

Indexed keywords

GABAPENTIN; GABAPENTIN ENACARBIL; PLACEBO;

ADVERSE OUTCOME; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL EFFECTIVENESS; DIZZINESS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; GASTROINTESTINAL DISEASE; HEADACHE; HUMAN; MORNING DOSAGE; NAUSEA; NEUROPROTECTION; OUTCOME ASSESSMENT; PAIN ASSESSMENT; POSTHERPETIC NEURALGIA; REVIEW; SECONDARY PREVENTION; SOMNOLENCE; TREATMENT INDICATION;

EID: 84889855672     PISSN: 11766336     EISSN: 1178203X     Source Type: Journal    
DOI: 10.2147/TCRM.S50212     Document Type: Review

References (27)

1. Doggrell SA. Pregabalin or morphine and gabapentin for neuropathic pain. Expert Opin Pharmacother. 2005;6(14):2535-2539.
2. Gupta R, Farquhar-Smith P. Post-herpetic neuralgia. Contin Educ Anaesth Crit Care Pain. 2012;12(4):181-185.
3. Bader MS, McKinsey DS. Viral infections in the elderly. The challenges of managing herpes zoster, influenza, and RSV. Postgrad Med. 2005;118(5):45-48, 51-54.
4. Wareham DW, Breuer J. Herpes zoster. BMJ. 2007;334(7605): 1211-1215.
5. Edmunds WJ, Brisson M, Rose JD. The epidemiology of herpes zoster and potential cost-effectiveness of vaccination in England and Wales. Vaccine. 2001;19(23-24):3076-3090.
6. Richter A, Anton SE, Koch P, Dennett SL. The impact of reducing dose frequency on health outcomes. Clin Ther. 2003;25(8):2307-2335.
7. Dworkin RH, O'Connor AB, Backonja M, etal. Pharmacologic management of neuropathic pain: evidence-based recommendations. Pain. 2007;132(3):237-251.
8. Dworkin RH, O'Connor AB, Audette J, etal. Recommendations for the pharmacological management of neuropathic pain: an overview and literature update. Mayo Clin Proc. 2010;85(Suppl 3):S3-S14.
9. American Society of Anesthesiologists Task Force on Chronic Pain Management; American Society of Regional Anesthesia and Pain Medicine. Practice guidelines for chronic pain management: an updated report by the American Society of Anesthesiologists Task Force on Chronic Pain Management and the American Society of Regional Anesthesia and Pain Medicine. Anesthesiology. 2010;112(4):810-833.
10. Attal N, Cruccu G, Baron R, etal; European Federation of Neurological Societies. EFNS guidelines for the pharmacological treatment of neuropathic pain: 2010revision. Eur J Neurol. 2010;17(9): 1113-1123.
11. Thomas B, Farquhar-Smith P. Extended-release gabapentin in post-herpetic neuralgia. Expert Opin Pharmacother. 2011;12(16): 2565-2571.
12. Eroglu C, Allen NJ, Susman MW, etal. Gabapentin receptor alpha2delta-1 is a neuronal thrombospondin receptor responsible for excitatory CNS synaptogenesis. Cell. 2009;139(2):380-392.
13. Gupta SK, Mahajan A, Tandon V. Gabapentin for the treatment of neuropathic pain. JK Science. 2004;6(3):113-114.
14. Cundy KC, Branch R, Chernov-Rogan T, etal. XP13512 [(+/-)-1-([(alpha-isobutanoyloxyethoxy)carbonyl] aminomethyl)-1-cyclohexane acetic acid], a novel gabapentin prodrug: I. Design, synthesis, enzymatic conversion to gabapentin, and transport by intestinal solute transporters. J Pharmacol Exp Ther. 2004;311(1):315-323.
15. Neurontin® (gabapentin) Caps, Tab, OS [prescribing information]. New York, NY: Pfizer Inc; 2013. Available from: http://labeling.pfizer.com/ShowLabeling.aspx?id=630. Accessed May 20, 2013.
16. Lal R, Sukbuntherng J, Luo W, Tovera J, Lassauzet ML, Cundy KC. Population pharmacokinetics and pharmacodynamics of gabapentin after administration of gabapentin enacarbil. J Clin Pharmacol. 2013;53(1):29-40.
17. US Food and Drug Administration. Highlights of prescribing information: HORIZANT™ (gabapentin encarbil). Silver Spring, MD; US Food and Drug Administration; 2011. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022399s000lbl.p df. Accessed May 19, 2013.
18. US Government Department of Veterans Affairs. Gabapentin Enacarbil (Horizant®) National Drug Monograph. Washington, DC: US Government Department of Veterans Affairs; 2012. Available from: http://www.pbm.va.gov/PBM/clinicalguidance/drugmonographs/GabapentinEnac arbilHorizantDrugMonograph.pdf. Accessed May 21, 2013.
19. Cundy KC, Annamalai T, Bu L, etal. XP13512 [(+/-)-1-([(alpha-isobutanoyloxyethoxy)carbonyl] aminomethyl)-1-cyclohexane acetic acid], a novel gabapentin prodrug: II. Improved oral bioavailability, dose proportionality, and colonic absorption compared with gabapentin in rats and monkeys. J Pharmacol Exp Ther. 2004;311(1):324-333.
20. Zhang L, Rainka M, Freeman R, etal. A randomized, double-blind, placebo-controlled trial to assess the efficacy and safety of gabapentin enacarbil in subjects with neuropathic pain associated with postherpetic neuralgia (PXN110748). J Pain. 2013;14(6):590-603.
21. Backonja MM, Canafax DM, Cundy KC. Efficacy of gabapentin enacarbil vs placebo in patients with postherpetic neuralgia and a pharmacokinetic comparison with oral gabapentin. Pain Med. 2011;12(7): 1098-1108.
22. Moore RA, Wiffen PJ, Derry S, McQuay HJ. Gabapentin for chronic neuropathic pain and fibromyalgia in adults. Cochrane Database Syst Rev. 2011;(3):CD007938.
23. Haslam C, Nurmikko T. Pharmacological treatment of neuropathic pain in older persons. Clin Interv Aging. 2008;3(1):111-120.
24. Lal R, Sukbuntherng J, Luo W, etal. Pharmacokinetics and tolerability of single escalating doses of gabapentin enacarbil: a randomized-sequence, double-blind, placebo-controlled crossover study in healthy volunteers. Clin Ther. 2009;31(8):1776-1786.
25. Chen D, Lal R, Zomorodi K, etal. Evaluation of gabapentin enacarbil on cardiac repolarization: a randomized, double-blind, placebo-and active-controlled, crossover thorough QT/QTc study in healthy adults. Clin Ther. 2012;34(2):351-362. e3.
26. Lal R, Sukbuntherng J, Luo W, etal. Clinical pharmacokinetic drug interaction studies of gabapentin enacarbil, a novel transported prodrug of gabapentin, with naproxen and cimetidine. Br J Clin Pharmacol. 2010;69(5):498-507.
27. US Food and Drug Administration. Highlights of prescribing information: LYRICA® (pregabalin). Silver Spring, MD; US Food and Drug Administration; 2011. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021446s026,0224 88s005lbl.pdf. Accessed May 19, 2013.